Dec 1, 2020 12:05pm
Amgen, Takeda and UCB will test their existing anti-inflammatory drugs in a new COVID-19 clinical trial called Community. (Getty/sudok1)
Even as the FDA has already approved or authorized several COVID-19 drugs, the search for better therapies is still underway—and despite some high-profile failures, repurposing existing drugs remains a strategy.
Now, three pharma companies have decided to tap their own portfolios in a new clinical trial among hospitalized patients.
Tuesday, Amgen, Takeda and UCB said they have kicked off a so-called adaptive trial to see whether any one of three drugs can rein in the uncontrolled inflammatory responses that afflict some COVID patients.
The three drugs are Amgen’s psoriasis and psoriatic arthritis med Otezla; an intravenous formulation of Takeda’s hereditary angioedema therapy Takhzyro; and UCB’s experimental autoimmune drug zilucoplan.
The trial, dubbed Community, will recruit a wide range of hospitalized patients, from those with mild symptoms all the way up to the point where the patient requires invasive ventilation or extracorporeal membrane oxygenation, commonly known as ECMO.
Adrenocorticotropic hormone-secreting (ACTH) price of viagra pills tumors These tumors cause abnormal production of the hormone adrenocorticotropin. Almonds Nutrition are likewise a rich root of magnesium, which encourages to upgrade the flood of blood, oxygen and nutrients to tissues, because they reduce blood viscosity, cholesterol and triglycerides, prevent platelet aggregation and decrease the risk sildenafil 100mg viagra of atherosclerosis. Also, well known as impotency worldwide, erectile dysfunction fluctuates from extra sexual tribulation for example diluted sex drive (result in poor sexual interest) or premature ejaculation even if frequently can viagra online from india be encounter together. This product can help you provide sensational feelings during sexual intercourse by helping you reach ecstatic orgasms. lowest price viagra “By enrolling both hospitalized intensive care unit and non-intensive care unit patients, the trial seeks to yield greater understanding of how therapeutic interventions may be used with hospitalized COVID-19 patients experiencing a range of symptoms,” the companies said.
[huge_it_slider id=”15″]The three drugmakers are part of the COVID R&D Alliance, a group of more than 20 biopharma firms formed to support drug development efforts in the pandemic. Under that collaboration frame, Takeda and Amgen previously partnered up with AbbVie in the I-SPY COVID study, evaluating Otezla, Takhzyro predecessor Firazyr and AbbVie’s experimental nonalcoholic steatohepatitis drug cenicriviroc in severe COVID patients who require high-flow oxygen but aren’t ill enough to need invasive ventilation.
The Community study will evaluate the time to confirmed clinical recovery as the primary endpoint, with death rate, oxygen-free recovery, clinical improvement and fitness for hospital discharge as key secondary endpoints.
Like the National Institutes of Health’s ACTT program, the Community trial also uses an adaptive platform, which allows for assessment of multiple candidates. As the trial moves forward, drugs that do not show benefits will be removed and other therapies, including antiviral, immunomodulating and vascular agents, may enter.
Otezla came in Amgen’s possession recently by way of an FTC-forced sale during Celgene’s merger with Bristol Myers Squibb. Zilucoplan landed at UCB through the Belgium company’s $2.5 billion acquisition of Ra Pharmaceuticals, and it’s in a phase 3 trial in myasthenia gravis patients.
So far, the FDA has officially greenlighted Gilead Sciences’ antiviral Veklury (remdesivir) to treat hospitalized COVID patients, and last month granted Eli Lilly’s arthritis med Olumiant an emergency use authorization to be used alongside the Gilead drug in patients who need oxygen support.
In addition, Lilly’s AbCellera-partnered anti-SARS-CoV-2 antibody bamlanivimab and Regeneron’s antibody cocktail of casirivimab and imdevimab have also scored FDA emergency nods, but only in the outpatient setting.